

THE UNIVERSITY OF TEXAS



## CURRICULUM VITAE

Yuan Ji, Ph.D.

### PRESENT TITLE AND AFFILIATION

#### Primary Appointment

Associate Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

#### Dual/Joint/Adjunct Appointment

Associate Professor, Statistics, Rice University, Houston, TX

### CITIZENSHIP

China, U.S. Permanent Resident

### OFFICE ADDRESS

The University of Texas MD Anderson Cancer Center  
1400 Pressler Street  
Unit Number: Unit 1411  
Houston, TX 77030  
Room Number: FCT4.6044  
Phone: (713) 794-4153  
Fax: (713) 563-4242

### EDUCATION

#### Degree-Granting Education

Fudan University, Shanghai, China, BA, 1997, Mathematics  
University of Minnesota, Twin Cities, MN, MS, 1999, Biostatistics  
University of Wisconsin-Madison, Madison, WI, PHD, 2003, Statistics

#### Postgraduate Training

N/A

### CREDENTIALS

#### Board Certification

N/A

#### Licensures

##### Active

N/A

##### Inactive

N/A

### EXPERIENCE/SERVICE

#### Academic Appointments

Assistant Professor, Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2003–8/2006

Assistant Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2006–8/2009

Associate Professor, Statistics, Rice University, Houston, TX, 9/2009–present

Associate Professor, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2009–present

#### Administrative Appointments/Responsibilities

Member of Search Committee, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005–present

Chair of the statistical analyst search committee, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 12/2008–present

Chair of the search committee for the Associate Director of Bioinformatic Analysis, Department of Bioinformatics and Computational Biology, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2009–present

#### **Other Appointments/Responsibilities**

Research Assistant, Community Programs for Clinical Research on AIDS (CPCRA), School of Public Health, University of Minnesota, Minneapolis, MN, 9/1997–1/2000

Research Assistant, School of Public Health, University of Minnesota, Minneapolis, MN, 1/2000–8/2000

Research Assistant, Department of Biostatistics and Medical Informatics, University of Wisconsin - Madison, Madison, WI, 9/2001–8/2002

#### **Endowed Positions**

N/A

#### **Consultantships**

N/A

#### **Military or Other Governmental Service**

N/A

#### **Institutional Committee Activities**

Institutional Review Board 2, Associate Member, 9/2008–8/2009

Institutional Review Board 2, Associate Member, 9/2010–8/2011

#### **HONORS AND AWARDS**

National Mathematical Modeling Contest, Department of Mathematics, Fudan University, China, 1995

International Mathematical Modeling Contest, Department of Mathematics, Fudan University, China, 1996

Merck Foundation Fellowship, Department of Biostatistics and Medical Informatics, University of Wisconsin-Madison, 2002

NSF Young Researcher Travel Grant, National Science Foundation, 2002

Student Travel Award and the Charles Sampson Award, The 25th annual Midwest Biopharmaceutical Statistics Workshop, Muncie, Indiana, 2002

Vilas Travel Fellowship, University of Wisconsin-Madison, Madison, Wisconsin, 2002

ENAR Student Award, International Biometric Society's Eastern North American Region (ENAR), Florida, 2003

#### **RESEARCH**

##### **Grants and Contracts**

###### **Funded**

Biostatistician, 10%, Cancer Center Support Grant - Biostatistics Resource (PP-SR21), 5 P30 CA016672 35, NIH/NCI, PI - John Mendelsohn, 7/1/2003–6/30/2013, \$1,833,480 (\$611,160/year)

Co-Investigator, Antigen Discovery and Development of Tumor-Specific Lymphoma Immunotherapy, 5 K23 CA123149 04, NIH/NCI, PI - Sattva Neelapu, 5/1/2007–4/30/2011, \$504,000 (\$126,000/year)

Co-Investigator, 5%, Translational Development of Novel Vaccine Therapies (PC-A), 7262-08-04, Leukemia and Lymphoma Society, PI - Larry Kwak, 10/1/2007–9/30/2012, \$325,335 (\$65,067/year)

Co-Investigator, 10%, SPORE in Brain Cancer (PP-2A), 5 P50 CA127001 03, NIH/NCI, PI - W K Alfred Yung, 9/1/2008–8/31/2013, \$399,221 (\$137,043/year)

Principal Investigator, 35%, Bayesian models for cancer prognosis by integrating diverse types of data, 5 R01 CA132897 03, NIH/NCI, 9/15/2008–7/31/2013, \$770,130 (\$125,130/year)

Principal Investigator, 35%, Bayesian models for cancer prognosis by integrating diverse types of data, 5 R01 CA132897 04, NIH/NCI, 9/15/2008–7/31/2013, \$770,130 (\$125,130/year)

Co-Investigator, 5%, Chemotherapy Resistance in Hispanic and African American Patients, KG090341 02, Komen for the Cure, PI - Ana Gonzalez-Angulo, 7/29/2009–7/28/2012, \$358,220 (\$119,501/year)

Co-Core Leader, 10%, UT M. D. Anderson Cancer Center Lymphoma SPORE - (PC-D), 5 P50 CA136411 02, NIH/NCI, PI - Anas Younes, 9/1/2009–8/31/2012, \$65,783 (\$33,315/year)

Investigator, 5%, Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC), 5 U24 CA143883 02, NIH/NCI, PI - John N Weinstein, 9/29/2009–7/31/2014, \$5,760,055 (\$1,119,408/year)

Investigator, Enhancing antitumor immunity with anti-PD-1 antibody in follicular lymphoma, 1 R21 CA143785 01, NIH/NCI, PI - Sattva Neelapu, 1/10/2010–12/31/2011, \$415,000 (\$207,500/year)

Collaborator, 3.37%, Towards Personalized Therapy of Resistant Triple Negative Breast Cancer, RSG-11-187-01-TBG 01, American Cancer Society (ACS), PI - Ana Maria Gonzalez-Angulo, 7/1/2011–6/30/2015, \$960,000 (\$150,000/year)

### Pending

Co-Investigator, 10%, A systems-biology approach to predict phenotypic affects for mammalian genes, 1 R21 HG006722-01, NIH/NCI, PI - Han Liang, 4/1/2012–3/31/2014, \$275,000 (\$125,000/year)

### Other

N/A

### Completed

Investigator, Therapy of CML (PP-2), 5 P01 CA049639 19, NIH/NCI, PI - Richard Champlin, 2/12/1997–2/28/2010, \$734,577 (\$146,915/year)

Investigator, 20%, University of Texas SPORE in Prostate Cancer (PC-B), 5 P50 CA09027 05, NIH/NCI, PI - Christopher Logothetis, 1/1/2004–10/31/2005, \$705,228 (\$141,046/year)

Co-Investigator, 5%, Breast SPORE Career Development Award - Identification of synthetic lethal targets interacting with mTOR inhibition in breast cancer cells expressing aberrant PI3K signaling network, 5 P50 CA116199 02, NIH/NCI, PI - Gabriel Hortobagyi, 9/28/2006–8/31/2007, \$38,851 (\$38,851/year)

Co-Investigator, 5%, Clinical Activity of MGCD-0103 in Hodgkin Lymphoma, 5 R21 CA133876 02, NIH/NCI, PI - Anas Younes, 7/8/2008–6/30/2010, \$360,000 (\$180,000/year)

### Not Funded

Co-Investigator, 5%, Polynuclear Platinums in Targeted and Combination Therapy, 1 R01 CA128991 01, NIH/NCI, PI - Oliver Bogler, 7/1/2007–6/30/2012, \$930,825 (\$186,165/year)

Co-Investigator, 5%, Immunologic mechanisms of extracorporeal photopheresis in cutaneous T-cell lymphomas: Induction of antigen-specific cytotoxic T cells or regulatory T cells?, N/A, National Blood Foundation, PI - Xiao Ni, 7/1/2008–6/30/2009, \$65,000 (\$65,000/year)

Investigator, 30%, Therapy of CML (PC-B), 2 P01 CA049639 20, NIH/NCI, PI - Richard Champlin, 12/1/2008–11/30/2013, \$929,009 (\$175,000/year)

Investigator, 5%, HDAC Inhibitor-based Therapy of Lymphoma, 1 R01 CA138420 01, NIH/NCI, PI - Anas Younes, 4/1/2009–3/31/2014, \$1,250,000 (\$250,000/year)

Investigator, 3%, T-cell Therapy for B-lineage Acute Lymphoblastic Leukemia, 1 R01 CA141303 01, NIH/NCI, PI - Laurence J.N. Cooper, 7/1/2009–6/30/2014, \$1,250,000 (\$250,000/year)

Co-Investigator, 5%, Development of Entinostat (SNDX-275) for patients with elapsed Hodgkin Lymphoma, 1 RC1 CA144834 01, NIH/NCI, PI - Anas Younes, 9/30/2009–9/29/2011, \$694,410 (\$347,200/year)

Principal Investigator, 15%, Bayesian Models for cancer prognosis by integrating diverse types of data, 3 R01 CA132897 02S1, NIH/NCI, 10/1/2009–9/30/2011, \$450,000 (\$225,000/year)

Co-Investigator, 10%, Enhancing antitumor immunity with anti-PI-1 antibody in follicular lymphoma, W81XWH-09-PRMRP-CTA, Department of Defense (DOD), PI - Sattva Neelapu, 12/1/2009–11/30/2013, \$1,400,000 (\$350,000/year)

Co-Investigator, 10%, Phosphorylated Fatty Acid Synthase and HER Signaling in Breast Cancer, 1 R01 CA143029 01, NIH/NCI, PI - Francisco J Esteva, 12/1/2009–11/30/2014, \$1,250,000 (\$250,000/year)

Collaborator, 5%, Molecular Characterization and Personalized Treatment of Residual Breast Carcinoma after Neoadjuvant Systemic Therapy, 100423, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Ana M Gonzalez Angulo, 2/1/2010–1/31/2014, \$1,266,528 (\$316,632/year)

Principal Investigator, 10%, Statistical Models for Differential Pathways, 100448, Cancer Prevention & Research Institute of Texas (CPRIT), 3/1/2010–2/28/2014, \$612,157 (\$149,746/year)

Collaborator, 2%, Targeting Cardiotoxicity of Anthracyclines through Selective Sensitization of Cancer Cells to Fas-mediated Apoptosis, 100574, Cancer Prevention & Research Institute of Texas (CPRIT), PI - Zuzana Berkova, 3/1/2010–2/28/2014, \$1,059,779 (\$264,945/year)

Investigator, 10%, Molecular Analysis of Human Breast Cancer to Facilitate Patient Selection for Novel Therapy (PP-2), 1 P01 CA148097 01, NIH/NCI, PI - Lajos Pusztai, 4/1/2010–3/31/2015, \$892,572 (\$168,201/year)

Collaborator, 5%, Personalized Therapy of Resistant Breast Cancer after Neoadjuvant Treatment, FReD 30495, American Cancer Society (ACS), PI - Ana Maria Gonzalez-Angulo, 7/1/2010–6/30/2014, \$953,812 (\$238,453/year)

Co-Investigator, 10%, Molecular Theranostics of Ovarian Cancer (PC-C), 1 P01 CA136397 01A2, NIH/NCI, PI - Anil K. Sood, 12/1/2010–11/30/2015, \$772,048 (\$136,001/year)

Co-Principal Investigator, 20%, Expression and evolution of young duplicate genes in the human genome, 1 R01 GM097266 01, NIH/NIGMS, PI - Han Liang, 4/1/2011–3/31/2015, \$1,125,000 (\$225,000/year)

Co-Investigator, 3%, Effector mechanisms of inducible epithelial resistance pneumonia, 1 R01 AI095279 01, NIH/NCI, PI - Scott Evans, 7/1/2011–6/30/2016, \$1,250,000 (\$250,000/year)

Principal Investigator, 10%, Next-generation biomarker based on pathway dependence, 1 R01 OD008924 01, NIH/OD, 9/1/2011–8/31/2016, \$1,250,000 (\$250,000/year)

## Protocols

### Funded

Collaborator, An Open Label Dose and Schedule Finding Trial to Evaluate the Safety and Efficacy of AMG 531 for Treatment of Severe Thrombocytopenia Due to Multi-Cycle Chemotherapy in Adult Subjects with Relapsed Aggressive Lymphoma, 2005-0749, PI - Fanale, 2006

Collaborator, Randomized, Double-Blind, Placebo Controlled Trial of Voraxaze in Patients with a Delayed MTX Clearance, 2006-0119, PI - Vadhan, 2006

Collaborator, A Phase 2, Open-Label Trial to Evaluate the Efficacy & Safety of MGCD0103 Administered in Combination w/ Azacitidine to Subjects w/ Relapsed or Refractory Hodgkin's or Non-Hodgkin's Lymphoma, & to Evaluate the Pharmacokinetics of MGCD0103, 2007-0536, PI - Younes, 2007

Collaborator, A Randomized Phase III Study of Rituximab with ABVD Versus Standard ABVD for Patients with Advanced-Stage Classical Hodgkin Lymphoma With Poor Risk Features (IPS Score greater than 2), 2007-0144, PI - Younes, 2007

Collaborator, Phase 2 Study of Rasburicase Administered by Two Different Schedules (Fixed Dosing vs. As Needed Dosing) in Patients at High Risk or Potential Risk for Tumor Lysis Syndrome, 2006-0918, PI - Vadhan, 2007

Collaborator, Single-Arm, Open-Label, Phase II Trial of Rituximab Plus Sargramostim For The Treatment of Newly Diagnosed Follicular B-Cell Lymphoma In Adults, 2006-0260, PI - McLaughlin, 2007

Collaborator, A Phase II Study of Revlimid in Combination with Rituximab as Initial Treatment for Patients with Indolent Non-Hodgkins Lymphoma (NHL), 2008-0042, PI - Samaniego, 2008

Collaborator, A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients with Relapsed/Refractory Classical Hodgkin Lymphoma, 2008-0604, PI - Michelle A. Fanale, 2009

Collaborator, Phase II Safety and Efficacy Study of the Monoclonal Antibody CT-011 in combination with Rituximab in Patients with Relapsed Follicular Lymphoma, 2009-0163, PI - Sattva S. Neelapu, 2009

Collaborator, Phase III Study Comparing Rituximab-supplemented ABVD (R-ABVD) with ABVD Followed by Involved-field Radiotherapy (ABVD-RT) in LIMITED-stage (STAGE I-IIA WITH NO AREAS OF BULK) Hodgkin's Lymphoma., 2009-0292, PI - Anas Younes, 2009  
 Collaborator, Phosphorylated Fatty Acid Synthase and HER Signaling in Breast Cancer: Correlative Study of Neoadjuvant Lapatinib followed by Trastuzumab-Based Therapy in Operable HER2+ Breast Cancer, 2009-0053, PI - Francisco J. Esteva, 2009

#### **Unfunded**

N/A

#### **Patents and Technology Licenses**

##### **Patents**

N/A

##### **Technology Licenses**

N/A

#### **Grant Reviewer/Service on Study Sections**

Neurogenesis and Cell Fate, NIH, Mail Reviewer, 2008

NIH study section (2009) ZGM1 PPBC-0 MT, NIH, pending, 2009

Special Emphasis Panel/Scientific Review Group 2009/10 ZRG1 BDA-A (58) R, NIH, Internet assisted Review (IAR), 2009

James and Esther King Biomedical Research Program and Bankhead-Coley General Program, Florida Department of Health, Reviewer, 2010

NMRC IRG, National Medical Research Council, Singapore, Reviewer, 2010

Computational Tool Development and Integrative Data Analysis for LINCS (U01), NIH, Member, 2011

Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) (U54) and Statistical Coordination Center for the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) (U01), NIH, Member, 2011

#### **PUBLICATIONS**

##### **Peer-Reviewed Original Research Articles**

1. Ji Y, Tsui KW, Kim K. A novel means of using gene clusters in a two-step empirical Bayes method for predicting classes of samples. *Bioinformatics* 21(7):1055-61, 4/2005. e-Pub 10/2004.
2. Ji Y, Wu C, Liu P, Wang J, Coombes KR. Applications of beta-mixture models in bioinformatics. *Bioinformatics* 21(9):2118-22, 5/2005. e-Pub 2/2005.
3. Kolonin MG, Sun J, Do KA, Vidal CI, Ji Y, Baggerly KA, Pasqualini R, Arap W. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. *FASEB J* 20(7):979-81, 5/2006. e-Pub 3/2006.
4. Yin G, Li Y, Ji Y. Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. *Biometrics* 62(3):777-84, 9/2006.
5. Ji Y, Tsui K-W, Kim KM. A two-stage empirical Bayes method for identifying differentially expressed genes. *Computational Statistics and Data Analysis*. 50:3592-604, 2006.
6. Ji Y, Coombes K, Zhang J, Wen S, Mitchell J, Pusztai L, Symmans WF, Wang J. RefSeq refinements of UniGene-based gene matching improve the correlation of expression measurements between two microarray platforms. *Appl Bioinformatics* 5(2):89-98, 2006.
7. Zhu R, Ji Y, Xiao L, Matin A. Testicular germ cell tumor susceptibility genes from the consomic 129.MOLF-Chr19 mouse strain. *Mamm Genome* 18(8):584-595, 8/2007. e-Pub 8/2007. PMID: PMC2647748.
8. Zhang J, Ji Y, Zhang L. Extracting three-way gene interactions from microarray data. *Bioinformatics* 23(21):2903-2909, 11/2007. e-Pub 10/2007.
9. Ji Y, Li Y, Yin G. Bayesian dose-finding designs for phase I clinical trials. *Statistica Sinica* 17:531-47, 2007.
10. Ji Y, Yin G, Tsui K-W, Kolonin M, Sun J, Arap W, Pasqualini R, Do K-A. Bayesian mixture models for complex high-dimension count data. *Applied Statistics* 56:139-152, 2007.
11. Ji Y, Li Y, Nebiyou Bekele B. Dose-finding in phase I clinical trials based on toxicity probability intervals. *Clin Trials* 4(3):235-44, 2007.

12. Sun M, Estrov Z, Ji Y, Coombes KR, Harris DH, Kurzrock R. "Curcumin (Diferuloylmethane) Alters the Expression Profiles of MicroRNAs in Human Pancreatic Cancer Cells." *Mol Cancer Ther* 7(3):464-473, 3/2008.
13. Ji Y, Lu Y, Mills GB. Bayesian models based on test statistics for multiple hypothesis testing problems. *Bioinformatics* 24(7):943-949, 4/2008. e-Pub 2/2008.
14. Bekele BN, Ji Y, Shen Y, Thall PF. Monitoring late-onset toxicities in phase I trials using predicted risks. *Biostatistics* 9(3):442-57, 7/2008. e-Pub 12/2007.
15. Miyazaki K, Yamaguchi M, Suguro M, Choi W, Ji Y, Xiao L, Zhang W, Ogawa S, Katayama N, Shiku H, Kobayashi T. Gene Expression Profiling of Diffuse Large B-cell Lymphoma Supervised by CD21 Expression. *Br J Haematol* 142(4):562-570, 8/2008. e-Pub 6/2008.
16. Li Y, Bekele BN, Ji Y, Cook JD. Dose-schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. *Stat Med* 27(24):4895-4913, 10/2008.
17. Hu B, Ji Y, Tsui KW. Bayesian estimation of inverse dose-response. *Biometrics* 64(4):1223-30, 12/2008. e-Pub 3/2008.
18. Fanale M, Fayad L, Pro B, Samaniego F, Zachariah G, Nunez C, Ji Y, Younes A. A phase I evaluation of bortezomib in combination with ice (BICE) as treatment for relapsed/refractory classical Hodgkin lymphoma. *Annals of Oncology* 19:236-236, 2008.
19. Berkova Z, Wang S, Wise JF, Maeng H, Ji Y, Samaniego F. Mechanism of Fas signaling regulation by human herpesvirus 8 K1 oncoprotein. *J Natl Cancer Inst* 101(6):399-411, 3/2009. e-Pub 3/2009. PMID: PMC2720696.
20. Ji Y, Bekele BN. Adaptive randomization for multi-arm comparative clinical trials based on joint efficacy/toxicity outcomes. *Biometrics* 65(3):876-84, 9/2009. e-Pub 1/2009.
21. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F, McLaughlin P, Hagemeister F, Neelapu S, Copeland A, Samuels BI, Loyer EM, Ji Y, Younes A. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan in Patients With Relapsed or Refractory Mantle Cell Lymphoma. *J Clin Oncol* 27(31):5213-8, 11/2009. e-Pub 9/2009.
22. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, Conrad CA. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. *Neuro Oncol* 12(3):233-42, 3/2010. e-Pub 1/2010. PMID: PMC2940588.
23. Bekele BN, Li Y, Ji Y. Risk-group-specific dose finding based on an average toxicity score. *Biometrics* 66(2):541-8, 6/2010. e-Pub 7/2009.
24. Hu B, Bekele BN, Ji Y. Adaptive Dose Insertion in Early Phase Clinical Trials. *Clin Trials*. e-Pub 9/2010.
25. Zhou X, Teegala S, Huen A, Ji Y, Fayad L, Hagemeister FB, Gladish G, Vadhan-Raj S. Incidence and Risk Factors of Venous Thromboembolic Events in Lymphoma. *Am J Med* 123(10):935-41, 10/2010.
26. Ji Y, Liu P, Li Y, Bekele BN. A modified toxicity probability interval method for dose-finding trials. *Clin Trials* 7(6):653-63, 12/2010. e-Pub 10/2010.
27. Baladandayuthapani V, Ji Y, Talluri R, Nieto-Barajas LE, Morris JS. Bayesian Random Segmentation Models to Identify Shared Copy Number Aberrations for Array CGH Data. *J Am Stat Assoc* 105(492):1358-1375, 12/2010. PMID: PMC3079218.
28. Fanale M, Fayad L, Pro B, Samaniego F, Liboon MJ, Nunez C, Horowitz S, Anderlini P, Popat U, Ji Y, Kwak LW, Younes A. Phase I Study of Bortezomib Plus ICE (BICE) for the Treatment of Relapsed/Refractory Hodgkin Lymphoma. *Br J Haematol*. e-Pub 4/2011.
29. Juna A, Khaskhely N, Buglio D, Shafer JA, Derenzini E, Bollard CM, Medeiros LJ, III, s A, Ji Y, Younes A. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. *Exp Hematol*. e-Pub 7/2011.
30. Cai G, Li H, Lu Y, Lee JH, Mueller P, Ji Y, Liang S. Accuracy of RNA-Seq and its dependence on sequencing depth. *BMC Bioinformatics*. In Press.
31. Ji Y, Feng L, Liu P, Shpall EJ, Kebriaei P, Champlin R, Berry D, Cooper LJJ. Bayesian Continual Reassessment Method for Dose-Finding Trials Infusing T Cells with Limited Sample Size. *Journal Biopharmaceutical Statistics*. In Press.
32. Yuan J, Mitra R, Quintana F, Jara A, Mueller P, Lu Y, Liu P, Liang S. BM-BC: A Bayesian method of base calling for Solexa sequence data. *BMC Bioinformatics*. In Press.

33. Ji, Y, Xu, Y, Zhang, Q, Tsui, K-W, Yuan, Y, Liang, S, Liang, H. BM-Map: Bayesian Mapping of Multireads for Next-Generation Sequencing Data. *Biometrics*. In Press.
34. Lee JH, Ji Y\*, Liang S, Cai G, Mueller P\*. On Differential Gene Expression Using RNA-Seq Data. *Cancer Informatics*. In Press.
35. Younes A, Oki Y, Bociek GR, Kuruvilla J, Fanale M, Neelapu S, Copeland A, Buglio D, Galal A, Besterman J, Li Z, Drouin M, Patterson T, Ward MR, Paulus JK, Ji Y, Medeiros LJ, and Martell, RE. Phase II Study of Mocetinostat (MGCD0103) In Patients with Relapsed and Refractory Classical Hodgkin Lymphoma. *Lancet Oncology*. In Press.
36. Xie F, Ji Y, Tremmel LT. A Bayesian Adaptive Design for Multi-Dose, Randomized, Placebo-Controlled Phase I/II Trials. *Clinical Trial*. Submitted.
37. Mitra R, Mueller, P\*, Liang, S, Yue, L, Ji Y\*. A Bayesian Graphical Model for ChIP-Seq Data on Histone Modifications. *JASA*. Submitted.
38. Talluri R, Baladandayuthapani V, Mallick BK, Ji Y, Coombes KR, Hennessey BT, Davies M. Bayesian Sparse Graphical Models for Classification with Application to Protein Expression Data. *JASA*. Submitted.
39. Liang H, Yuan Y, Norris C, Xu Y, Tsui KW, Ji Y. BM-Map: an efficient software package for accurately allocating multireads of RNA-seq data. *Genome Biology*. Submitted.
40. Telesca D, Mueller P, Kornblau S, Ji Y. Modeling Protein Expression and Protein Signaling Pathways. *JASA*. Submitted.
41. Chu F, Foglietta M, Nattamai D, Lee ST, Yamazaki T, Orozco NM, Dong C, Vence LM, Radvanyi L, Younes A, Ji Y, Neelapu SS. PD-1 expression on T cells in follicular lymphoma. *Blood*. Submitted.
42. Jona A, Khaskhely N, Buglio D, Shafer JA, Derenzini E, Bollard C, Medeiros LJ, Illes A, Ji Y, Younes A. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. *Experimental Hematology*. Submitted.
43. Derenzini E, Buglio D, Katayama H, Ji Y, Davis E, Sen S, Younes A. The JAK2 inhibitor AZD1480 induces cell death in STAT3 dependent and STAT3 independent mechanisms and paradoxically activates ERK in Hodgkin Lymphoma. *Molecular Cancer Therapeutics*. Submitted.
44. Nieto-Barajas L, Mueller P, Ji Y, Lu Y, Mills, G. Time Series Dependent Dirichlet. *Biometrics*. Submitted.

**Invited Articles**

N/A

**Editorials**

N/A

**Other Articles**

N/A

**Abstracts**

1. Buglio, D, Palakurthi, S, Vega-Vasquez, F, Neelapu, S, Berry, D, Ji, Y, Byth, K, Younes, A. Inhibition of Tak-1 by AZD4248 impairs NF-kB activation, downregulates XIAP and activate caspase-9 inducing apoptosis in mantle cell lymphoma. *ASH 2010*. Submitted.

**Book Chapters**

N/A

**Books (edited and written)**

N/A

**Letters to the Editor**

N/A

**Manuals, Teaching Aids, Other Teaching Publications**

N/A

**Other Publications**

N/A

**EDITORIAL AND REVIEW ACTIVITIES****Editor/Service on Editorial Board(s)**

N/A

**Member of Editorial Review Board**

N/A

**Journal Reviewer**

Reviewer, Applied Statistics, 2003–present  
Reviewer, Bayesian Analysis, 2003–present  
Reviewer, Bioinformatics, 2003–present  
Reviewer, Biometrics, 2003–present  
Reviewer, Briefings in Bioinformatics, 2003–present  
Reviewer, Journal of Statistical Planning and Inference, 2003–present  
Reviewer, BMC Bioinformatics, 2007–present  
Reviewer, Journal of Biopharmaceutical Statistics, 2007–present  
Reviewer, Lifetime Data Analysis, 2007–present  
Reviewer, Biostatistics, 2008–present  
Reviewer, Clinical Trials, 2008–present  
Reviewer, Computational Statistics and Data Analysis, 2008–present  
Reviewer, Statistics in Medicine, 2008–present

**Other Editorial and Review Activities**

N/A

**TEACHING**

**Teaching Within Current Institution - The University of Texas MD Anderson Cancer Center**

**Formal Teaching**

**Courses Taught**

Instructor, Introduction to Mathematical Probability, The University of Texas Graduate School of Biomedical Sciences, Course Hours: 3  
Fall, 9/2004–12/2004  
Instructor, Introduction to Mathematical Probability, The University of Texas Graduate School of Biomedical Sciences, Course Hours: 3  
Fall 2005, 9/2005–12/2005  
Instructor, Introduction to Mathematical Statistics, The University of Texas Graduate School of Biomedical Sciences, Course Hours: 3  
Spring 2006, 1/2006–5/2006  
Instructor, Introduction to Mathematical Probability, The University of Texas Graduate School of Biomedical Sciences  
Fall 2006, 9/2006–12/2006  
Instructor, Advanced Statistical Methods for the Analysis of Gene Expression and Proteomics, The University of Texas Graduate School of Biomedical Sciences, Rice University, Course Hours: 3  
Spring, 1/2008–5/2008

**Training Programs**

N/A

**Other Formal Teaching**

N/A

**Supervisory Teaching**

**Committees**

**Advisory Committees**

Member, M.S. Advisory Committee, The University of Texas Graduate School of Biomedical Sciences, Kline Keith, 2005–2006  
Member, M.S. Advisory Committee, The University of Texas Graduate School of Biomedical Sciences, Jackson Lori, 2006–2007  
Member, Ph.D. Advisory Committee, The University of Texas Graduate School of Biomedical Sciences, Hennessey Violeta, 2006–2010  
Member, M.S. Advisory Committee, The University of Texas Graduate School of Biomedical Sciences, Gallegos Juan, 2006–present  
Member, Ph.D. Advisory Committee, The University of Texas Graduate School of Biomedical Sciences, Yan Lin, 2006–present

**Supervisory Committees**

Member, M.S. Supervisory Committee, The University of Texas Graduate School of Biomedical Sciences, Kline Keith, 2006–2007

**Examining Committees**

Member, Graduate Qualify Examining Committee, UT GSBS, Juan Gallegos, Violeta Hennessey, Hua Li, and Lin Yang, PhD, 9/2007–present

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

N/A

**Graduate Students**

Research Mentor (joint), Filippo Trentini, 11/2009–7/2010

Research Mentor (joint), Maria Anna Di Lucca, 11/2009–7/2010

**Postdoctoral Research Fellows**

Research Mentor (joint), Donatello Telesca, 9/2008–8/2009

Research Mentor (joint with Peter Mueller), Riten Mitra, 4/2010

Research Mentor (Joint with Peter Mueller), Juhee Lee, 7/2010

**Clinical Residents and Fellows**

N/A

**Other Supervisory Teaching**

N/A

**Teaching Outside of Current Institution**

**Formal Teaching**

**Courses Taught**

Instructor, Advanced Bayesian Statistics, Rice University, Course Number: STAT 552,

Course Hours: 3

Spring 2010, 1/2010–5/2010

**Training Programs**

N/A

**Other Formal Teaching**

N/A

**Supervisory Teaching**

**Committees**

**Advisory Committees**

Member, Advisory, GSBS, Lin Yang, PhD, 1/2007–10/2009

Member, Advisory, GSBS, Chunyan Cai, PhD, 12/2008–present

**Supervisory Committees**

Member, Supervisory Committee, GSBS, Hua Li, PhD, 1/2009–present

Member, Supervisory Committee, GSBS, Violetta Hennessey, PhD, 2/2009–8/2010

Member, Supervisory Committee, GSBS, Juan Gallegos, M.S., 8/2009–present

Member, Supervisory Committee, GSBS, Lin Yang, PhD, 7/2010–present

**Examining Committees**

Member, Examining Committee, GSBS, Chunyan Cai, 1/2010

Member, Examining Committee, GSBS, Haiying Pang, 2/2010

Member, Examining Committee, GSBS, Pan Tong, 8/2010

**Direct Supervision**

**Undergraduate and Allied Health Students**

N/A

**Medical Students**

N/A

**Graduate Students**

N/A

**Postdoctoral Research Fellows**

N/A

**Clinical Residents and Fellows**

N/A

**Other Supervisory Teaching**

N/A

**CONFERENCES AND SYMPOSIA**

**Organization of Conferences/Symposia (Include chairing session)**

International Chinese Statistical Association, Indianapolis, IN, Session Organizer, 6/2008

ENAR, Institute of Mathematical Statistics, San Antonio, Session Organizer, 3/2009

International Chinese Statistical Association, Guangzhou, China, Chair, 12/2010

**Presentations at National or International Conferences**

**Invited**

Bayesian models for phage display experiments, The BARDS Fellowship Symposium, Somerset, NJ, 7/2004

Decision-theoretical type of adaptive designs for phase I clinical trials, Barnett International 2nd annual meeting in adaptive designs for clinical trials: statistical methodologies and applications, London, 12/2004

Bayesian designs for dose-finding trials based on toxicity, Barnett International 3rd annual meeting in adaptive designs for clinical trials: statistical methodologies and applications, Brussels, Belgium, 12/2005

An Introduction to Bayesian methods, The Jiangxi University of Finance and Economics, Nanchang, China, 10/2006

Bayesian dose-finding in oncology clinical trials based on toxicity posterior probabilities, The 4th Chinese Conference on Oncology, Tianjin, China, 10/2006

Monitoring late onset toxicities in phase I trials using predicted risks, ENAR 2007, Atlanta, GA, 3/2007

Dose-finding in oncology clinical trials based on toxicity probability intervals, ICSA 2007, Raleigh, NC, 6/2007

Adaptive design for early phase clinical trials, First international symposium on biopharmaceutical statistics, The International Society for Biopharmaceutical Statistics, Shanghai, China, 6/30/2008

Practical Bayesian design for oncology dose-finding trials, 2008 Joint Statistical Meeting, American Statistical Association, Denver, CO, 8/5/2008

Bayesian base calling for Solexa sequencing data, International Chinese Statistical Association, International Chinese Statistical Association, Indianapolis, IN, 6/21/2010

Bayesian Models for Genetic Pathways, 2010 Joint Statistical Meeting, 2010 Joint Statistical Meeting, Vancouver, BC, Canada, 8/2/2010

Bayesian models for the Integration of mRNA expression and DNA copy number data, ICSA, International Chinese Statistical Association, Guangzhou, China, 12/20/2010

A Bayesian Graphical Model for ChIP-Seq Data on Histone Modifications, ENAR, Miami, FL, 3/2011

From Intensity to Counts: Statistical Issues in Next-Generation Sequencing Data, IISA, Raleigh, NC, 4/2011

A Bayesian Adaptive Design for Multi-Dose, Randomized, Placebo-Controlled Phase I/II Trials, ICSA, New York, NY, 6/2011

**Other, Including Scientific Exhibitions**

Microarray data analysis: A Bayesian Perspective, Graduate School Council Forum, University of Wisconsin-Madison, Madison, WI, 2/2002

Bayesian classification for microarray data, The 25th Annual Midwest Biopharmaceutical Statistics Workshop, Muncie, IN, 5/2002

Bayesian classification for microarray data, Frontiers of Statistical Research: A Celebration of the 40th Anniversary of the Department of Statistics at Texas A&M University, Texas A&M University, College Station, TX, 10/2002

Bayesian classification for microarray gene expression data, ENAR 2003, Tampa, FL, 4/2003

Bayesian models for high-dimensional count data, The 2nd Lehmann Symposium, Houston, TX, 5/2004

Poisson mixture models for high-dimensional count data, The Joint Statistical Meetings, Toronto, Canada, 8/2004

Bayesian adaptive dose-finding designs for phase I clinical trials, ENAR 2005, Austin, TX, 3/2005

Bayesian dose-finding designs, ENAR 2006, Tampa, FL, 3/2006

Dose-finding in oncology clinical trials based on posterior toxicity intervals, poster, Valencia 8 World Conference, Alicante, Spain, 6/2006

Dose-finding in oncology clinical trials based on toxicity probability intervals, IBC 2006, Montreal, Canada, 7/2006

Bayesian Adaptive Designs for Early Phase Oncology Trials, BASS XV Conference, Savannah, GA, 11/3/2008

Unit Probability Mass--A calibration-free method for dose finding oncology trials, BASS XXI Conference, Savannah, GA, 10/9/2009

#### **Seminar Invitations from Other Institutions**

Introduction to Bayes and empirical Bayes method with application on microarray experiments, The Bradfield Lab, University of Wisconsin, Madison, WI, 1/2002

Microarray data analysis: A Bayesian Perspective, Graduate School Council Forum, University of Wisconsin, Madison, WI, 2/2002

Application of the Bayesian approach and the mixture model in Bioinformatics research, School of Public Health, The University of Texas Health Science Center, Houston, TX, 1/2004

Adaptive designs for early phase clinical trials, School of Public Health, The University of Texas, Houston, TX, 10/2007

Bayesian Adaptive Designs for Early Phase Oncology Trials, Rice University, Department of Statistics, Houston, TX, 9/8/2008

Bayesian Segmentation Models for arrayCGH Data, Carnegie Mellon University, Pittsburgh, PA, 3/30/2009

Bayesian Models for Protein Pathways, The University of Texas, Biostatistics, SPH, Houston, TX, 2/23/2010

Bayesian models for genetic pathways, University of Wisconsin-Madison, University of Wisconsin-Madison, Madison, WI, 4/30/2010

A Quantitative Mind -- Medicine & Biology in 21st Century, Rush Medical College, Chicago, IL, 5/19/2010

Bayesian models for genetic pathways, University of California -- Davis, Biostatistics, Davis, CA, 12/4/2010

From Intensities to Counts: Statistical Issues in RNA-Seq Data, Fudan University, Biostatistics, Shanghai, China, 1/4/2011

Bayesian models for biomedical research, Northshore University Healthcare System, Informatics, Chicago, IL, 7/2011

#### **Lectureships and Visiting Professorships**

N/A

#### **Other Presentations at State and Local Conferences**

Bio-informatics for Pathway Analysis, 2009 Breast Cancer Research Program Fall Annual Retreat Conference Agenda, Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Breast Medical Oncology, Houston, TX, 11/14/2009

### **PROFESSIONAL MEMBERSHIPS/ACTIVITIES**

#### **Professional Society Activities, with Offices Held**

##### **National and International**

American Statistical Association

Member, 2002–present

Institute of Mathematical Statistics

Member, 2003–present

International Biometric Society

Member, 2003–present

##### **Local/State**

Houston Area Chapter, American Statistical Association, Houston, TX

Member, 2003–present

President Elect, 2006–2007

President, 2007–2008

Yuan Ji, Ph.D.

**UNIQUE ACTIVITIES**

N/A

**DATE OF LAST CV UPDATE**

9/7/2011

Yuan Ji, Ph.D.